# Soligenix Inc. (SNGX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $759,804.989  
**Price:** $0.46 (+6.42%)

> Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. It operates through two primary segments: Specialized BioTherapeutics, which targets therapies for conditions like cutaneous T-cell lymphoma with products such as HyBryte, and Public Health Solutions, addressing vaccines and treatments for biological threats and infectious diseases. The company advances innovative biopharmaceuticals, including synthetic hypericin formulations, emphasizing rapid response and strong safety profiles in clinical studies. Soligenix Inc. plays a vital role in the biopharma sector by addressing niche markets for orphan drugs and emergency countermeasures, contributing to advancements in rare disease management and public health preparedness. Founded in 1987 and headquartered in Princeton, New Jersey, it continues to prioritize late-stage development in these specialized areas.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2024 | $119,371 | — | -$9M | -$8M | — |
| 2023 | $839,359 | $97,311 | -$8M | -$6M | — |
| 2022 | $948,911 | $398,089 | -$14M | -$14M | — |
| 2021 | $824,268 | $95,628 | -$13M | -$13M | — |
| 2020 | $2M | $538,498 | -$19M | -$18M | — |
| 2019 | $5M | $1M | -$11M | -$9M | — |
| 2018 | $5M | $643,733 | -$9M | -$9M | — |
| 2017 | $5M | $1M | -$8M | -$7M | — |
| 2016 | $10M | $2M | -$6M | -$3M | — |
| 2015 | $9M | $2M | -$7M | -$8M | — |
| 2014 | $7M | $2M | -$11M | -$7M | — |
| 2013 | $3M | $679,867 | -$7M | -$10M | — |
| 2012 | $3M | $551,545 | -$5M | -$4M | — |
| 2011 | $8M | $6M | -$3M | -$2M | — |
| 2010 | $2M | $309,226 | -$8M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2024 | $9M | $5M | $4M | — | — |
| 2023 | $10M | $7M | $3M | — | $1M |
| 2022 | $14M | $17M | -$2M | — | — |
| 2021 | $27M | $16M | $11M | $26M | — |
| 2020 | $20M | $16M | $4M | $19M | — |
| 2019 | $8M | $6M | $1M | $5M | — |
| 2018 | $10M | $4M | $6M | $9M | — |
| 2017 | $10M | $3M | $6M | $8M | — |
| 2016 | $10M | $3M | $7M | $9M | — |
| 2015 | $7M | $7M | -$18,309 | $5M | — |
| 2014 | $7M | $7M | -$153,889 | $6M | — |
| 2013 | $8M | $10M | -$2M | $6M | — |
| 2012 | $5M | $1M | $4M | $3M | — |
| 2011 | $8M | $1M | $7M | $6M | — |
| 2010 | $9M | $2M | $7M | $7M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$10M | $5,883 | -$10M |
| 2024 | -$8M | — | — |
| 2023 | -$9M | — | — |
| 2022 | -$13M | — | — |
| 2021 | -$12M | — | — |
| 2020 | -$11M | — | — |
| 2019 | -$8M | — | — |
| 2018 | -$7M | — | — |
| 2017 | -$7M | — | — |
| 2016 | -$5M | — | — |
| 2015 | -$5M | — | — |
| 2014 | -$2M | — | — |
| 2013 | -$4M | — | — |
| 2012 | $3M | — | — |
| 2011 | -$2M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/SNGX)